Childhood myopia poses a massive public health challenge worldwide, particularly across rapidly urbanizing societies. Clinicians now direct significant attention toward halting early refractive changes before structural axial elongation accelerates. Recently, investigators published pivotal clinical trial findings on the therapeutic use of low-dose atropine in premyopia among pediatric cohorts. Premyopia characterizes eyes exhibiting hyperopic reserve depletion, placing young children at imminent risk of developing progressive myopia. When children present with unilateral myopia, their fellow premyopic eye typically follows an aggressive path toward axial expansion. Therefore, evaluating whether topical pharmacological prophylaxis preserves refractive stability represents an essential clinical objective.

Understanding Unilateral Myopia and Premyopic Risk

Unilateral myopia offers an ideal internal control model to evaluate refractive shifts in young pediatric cohorts. In routine clinical practice, ophthalmologists frequently observe that the non-myopic fellow eye eventually develops myopia. Genetics, screen exposure, and indoor lifestyles drive bilateral axial expansion simultaneously. However, refractive asymmetry frequently delays targeted intervention in the fellow eye until structural elongation has already advanced. Premyopia represents a critical intermediate phase where an eye has lost age-normal hyperopia. Consequently, identifying this therapeutic window allows eye care specialists to initiate preventive measures early. Younger age at onset correlates strongly with higher ultimate dioptric errors and vision-threatening retinal complications in adulthood. Therefore, preventive protocols aim to delay myopia onset, which substantially reduces lifetime ocular morbidity.

Methodological Framework of the Clinical Trial

The investigated clinical trial enrolled 104 pediatric participants aged 4 to 12 years over a 12-month period. All children presented with one myopic eye alongside one fellow premyopic eye at baseline. Researchers assigned participants into three distinct cohorts to test topical regimens rigorously. The first cohort received no pharmacological drops, serving as the observational control group. The second cohort received 0.01% topical atropine exclusively in the myopic eye, leaving the fellow eye untreated. Finally, the third cohort received bilateral 0.01% atropine intervention, applying daily drops to both eyes. Masked clinicians measured cycloplegic spherical equivalent refraction and optical axial length every three months. Additionally, investigators employed generalized estimating equations and Cox regression to capture myopic shift and onset rates accurately.

Efficacy of Low-Dose Atropine in Premyopia Progression

The trial demonstrated striking differences in refractive outcomes across the study cohorts. In the no-intervention group, myopic eyes progressed significantly faster than fellow premyopic eyes over twelve months. Specifically, untreated myopic eyes displayed an adjusted interocular difference of -0.19 diopters and 0.08 millimeters greater axial elongation. However, bilateral intervention altered this trajectory significantly in premyopic eyes. Premyopic eyes receiving low-dose atropine in premyopia exhibited 0.21 diopters less progression and 0.14 millimeters less axial elongation than untreated premyopic eyes in the monocular group. Furthermore, bilateral treatment halved the risk of a fast myopic shift compared to completely untreated controls. Cox regression confirmed that low-dose atropine reduced the hazard of myopia onset by 50%.

Mechanisms of Muscarinic Antagonism in Scleral Remodeling

Understanding the biochemical pathway of topical atropine helps clinicians appreciate why low concentrations modulate ocular expansion effectively. Although historically classified as an accommodative cycloplegic agent, atropine halts axial elongation through non-accommodative signaling cascades. Muscarinic acetylcholine receptors, specifically subtypes M1 and M4, reside extensively within the retina, choroid, and sclera. When atropine binds these ocular receptors, it triggers local biochemical mediators that suppress scleral matrix degradation. Furthermore, atropine stimulates glycosaminoglycan synthesis and stabilizes type I collagen fibrils within the extracellular scleral matrix. This structural reinforcement prevents posterior ocular wall stretching. In addition, topical atropine induces transient choroidal thickening, improving microcirculation. Consequently, low concentrations such as 0.01% suppress axial elongation while preserving pupil dynamics and clear near vision.

Clinical Implications for Pediatric Eye Care in India

The clinical relevance of premyopia intervention holds enormous value for medical practitioners across India. Rapid urbanization, reduced outdoor playtime, and intense digital screen exposure have triggered alarming increases in childhood myopia nationwide. Indian clinicians frequently encounter young school-age children who present with early anisometropia or borderline hyperopia. Because unilateral myopia often advances into bilateral visual impairment, timely prophylaxis is essential. Ophthalmologists should actively screen susceptible children using cycloplegic autorefraction rather than relying solely on visual acuity tests. When clinicians detect unilateral myopia with fellow-eye hyperopic depletion, starting bilateral 0.01% atropine offers a proactive strategy. Moreover, 0.01% atropine formulations are widely manufactured, affordable, and readily accessible across India, ensuring high parental acceptance and excellent therapeutic compliance.

Safety, Monitoring Protocols, and Practical Considerations

Introducing pharmacological prophylaxis in premyopic children requires systematic clinical monitoring and diligent safety evaluation. Low-dose 0.01% atropine demonstrates an exceptional safety profile, producing negligible systemic absorption and minimal pupillary mydriasis. Most pediatric patients tolerate nightly drops without experiencing photophobia, headaches, or blurred near vision. However, clinicians should document baseline visual acuity, pupil diameter, and accommodative amplitude before initiating therapy. Follow-up examinations every three to six months enable practitioners to track axial length changes and cycloplegic refraction precisely. If axial elongation continues rapidly, clinicians can consider titrating concentrations to 0.02% or 0.05% based on clinical response. Furthermore, maintaining therapy for at least one to two years stabilizes refractive trajectories until the child matures.

How does low-dose atropine differ from standard cycloplegic concentrations in pediatric management?

Standard atropine solutions at 1% concentration cause pronounced cycloplegia and marked pupillary dilation, often resulting in prolonged photophobia, glare, and blurred near vision. In contrast, low-dose atropine formulations, specifically 0.01%, modulate scleral remodeling and choroidal signaling pathways without significantly paralyzing the ciliary muscle. As a result, children tolerate daily low-dose drops exceptionally well, experiencing minimal pupil dilation, maintaining crisp near accommodation, and adhering reliably to multi-year prophylactic treatment regimens without scholastic disruption.

Which clinical criteria define premyopia in young children requiring monitoring?

Premyopia is clinically characterized by a refractive state between +0.75 diopters and -0.50 diopters in children who exhibit diminished age-expected hyperopia. When high-risk ocular factors, including positive parental myopia, increased near-work demands, or existing unilateral myopia in the fellow eye, accompany this borderline refraction, the risk of rapid progression escalates substantially. Consequently, identifying children during this pre-myopic stage allows timely clinical surveillance and pharmacological intervention before overt axial lengthening triggers permanent refractive deficits.

Should clinicians initiate bilateral therapy when myopia presents only unilaterally?

Yes, bilateral therapy is highly recommended because the non-myopic fellow eye shares identical genetic, behavioral, and environmental exposures, making bilateral myopia almost inevitable. Clinical trials demonstrate that monocular treatment leaves the premyopic eye vulnerable to accelerated axial elongation and rapid myopic shift. By applying low-dose atropine bilaterally, clinicians safeguard the premyopic fellow eye from progressing, reduce interocular anisometropia, and decrease the cumulative lifetime risk of sight-threatening pathological complications associated with early-onset juvenile myopia.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Healthcare professionals must exercise their independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Ye C et al. Premyopia Progression and Low-Dose Atropine Intervention in Children with Unilateral Myopia. Curr Eye Res. 2026 Oct 03. doi: 10.1080/02713683.2026.2728921. PMID: 42829343.
2. Lee SH, Tseng BY, Wang JH, Chiu CJ. Efficacy and Safety of Low-Dose Atropine on Myopia Prevention in Premyopic Children: Systematic Review and Meta-Analysis. J Formos Med Assoc. 2025;124(3):289-298.
3. Zadnik K, Schulman E, Flitcroft I, et al. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023;141(10):990-999.
4. Repka MX, Weise KK, Chandler DL, et al. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmol. 2023;141(8):756-765.